114834-09-2

Basic information

• Product Name: 6-(1H-Pyrazol-1-yl)pyrimidin-4-amine
• Synonyms: 6-(1H-Pyrazol-1-yl)pyrimidin-4-amine
• CAS NO: 114834-09-2
• Molecular Formula: C7H7N5
• Molecular Weight: 161.17
• Mol File: 114834-09-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-(1H-Pyrazol-1-yl)pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(1H-Pyrazol-1-yl)pyrimidin-4-amine(114834-09-2)
• EPA Substance Registry System: 6-(1H-Pyrazol-1-yl)pyrimidin-4-amine(114834-09-2)

Safety Data

• Hazardous Substances Data: 114834-09-2(Hazardous Substances Data)

Usage

Description

6-(1H-Pyrazol-1-yl)pyrimidin-4-amine is an organic compound with the molecular formula C8H7N5. It is a heterocyclic compound, featuring a pyrimidine ring fused with a pyrazole ring. 6-(1H-Pyrazol-1-yl)pyrimidin-4-amine is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
6-(1H-Pyrazol-1-yl)pyrimidin-4-amine is used as a reagent for the development of selective α7 nAChR partial agonists. These agonists are designed to target and modulate the activity of the α7 nicotinic acetylcholine receptor, which plays a crucial role in cognitive functions. The compound is particularly useful in the treatment of cognitive deficits associated with schizophrenia, a mental disorder characterized by a range of cognitive and emotional disturbances.
The application of 6-(1H-Pyrazol-1-yl)pyrimidin-4-amine in the pharmaceutical industry is based on its ability to interact with the α7 nAChR, which is believed to be involved in various cognitive processes. By acting as a partial agonist, this compound can potentially improve cognitive function in patients with schizophrenia, offering a new avenue for therapeutic intervention.

Upstream product

• 114833-95-3 4-chloro-6-(1H-pyrazol-1-yl)pyrimidine 
• 1336-21-6 ammonium hydroxide 
• 288-13-1 NH-pyrazole 
• 5305-59-9 4-amino-6-chloropyrimidine 

Relevant articles and documents

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia

The therapeutic treatment of negative symptoms and cognitive dysfunction associated with schizophrenia is a significant unmet medical need. Preclinical literature indicates that α7 neuronal nicotinic acetylcholine (nACh) receptor agonists may provide an effective approach to treating cognitive dysfunction in schizophrenia. We report herein the discovery and evaluation of 1c (BMS-933043), a novel and potent α7 nACh receptor partial agonist with high selectivity against other nicotinic acetylcholine receptor subtypes (>100-fold) and the 5-HT3A receptor (>300-fold). In vivo activity was demonstrated in a preclinical model of cognitive impairment, mouse novel object recognition. BMS-933043 has completed Phase I clinical trials.

Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents

Starting from a screening-hit compound, via structure modifications and optimizations, a series of nonfused and nonassembly pyrimidinylthiourea derivatives (2-5) was designed, synthesized, and evaluated as novel multifunctional agents against Alzheimer's disease. Biological activity results demonstrated that compounds 5r and 5t exhibited potent inhibition and excellent selectivity toward acetylcholinesterase (AChE, 5r, IC50 = 0.204 μM, SI > 196; 5t, IC50 = 0.067 μM, SI > 597), specific metal-chelating ability, significant antioxidant effects, modulation of metal-induced Aβ aggregation, inhibition of ROS production by copper redox cycle, low cytotoxicity, and moderate neuroprotection to human neuroblastoma SH-SY5Y cells. Moreover, compound 5r displayed appropriate blood-brain barrier (BBB) permeability both in vitro and in vivo and could improve memory and cognitive function of scopolamine-induced amnesia mice. The multifunctional profiles of 5r and its effectivity in AD mice highlight these structurally distinct pyrimidinylthiourea derivatives as prospective prototypes in the research of innovative multifunctional drugs for Alzheimer's disease.

Synthesis and cytoprotective antiulcer activity of 2- or 4-(1H-pyrazol- 1-yl)pyrimidine derivatives related to mepirizole and dulcerozine

(1H-Pyrazol-1-yl)-, (1H-imidazol-1-yl)-, and (1H-1,2,4-triazol-1- yl)pyrimidines were prepared and evaluated for cytoprotective antiulcer activity. Among them, 4-methoxy-6-methyl-2-(1H-pyrazol-1-yl)pyrimidine (18) showed potent inhibition of the HCl-ethanol-induced and water-immersion stress-induced ulcers in rats, as well as low acute toxicity.